160 related articles for article (PubMed ID: 21562465)
1. Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Price ET; Pacanowski MA; Martin MA; Cooper-DeHoff RM; Pepine CJ; Zineh I; Johnson JA
Pharmacogenet Genomics; 2011 Jun; 21(6):333-40. PubMed ID: 21562465
[TBL] [Abstract][Full Text] [Related]
2. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
3. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Beitelshees AL; Gong Y; Wang D; Schork NJ; Cooper-Dehoff RM; Langaee TY; Shriver MD; Sadee W; Knot HJ; Pepine CJ; Johnson JA;
Pharmacogenet Genomics; 2007 Sep; 17(9):719-29. PubMed ID: 17700361
[TBL] [Abstract][Full Text] [Related]
4. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Vandell AG; Lobmeyer MT; Gawronski BE; Langaee TY; Gong Y; Gums JG; Beitelshees AL; Turner ST; Chapman AB; Cooper-DeHoff RM; Bailey KR; Boerwinkle E; Pepine CJ; Liggett SB; Johnson JA
Hypertension; 2012 Oct; 60(4):957-64. PubMed ID: 22949529
[TBL] [Abstract][Full Text] [Related]
5. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
[TBL] [Abstract][Full Text] [Related]
6. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Cooper-DeHoff RM; Handberg EM; Mancia G; Zhou Q; Champion A; Legler UF; Pepine CJ
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1329-40. PubMed ID: 19900016
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Bakris GL; Gaxiola E; Messerli FH; Mancia G; Erdine S; Cooper-DeHoff R; Pepine CJ;
Hypertension; 2004 Nov; 44(5):637-42. PubMed ID: 15381674
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
Cooper-DeHoff RM; Aranda JM; Gaxiola E; Cangiano JL; Garcia-Barreto D; Conti CR; Hewkin A; Pepine CJ;
Am Heart J; 2006 May; 151(5):1072-9. PubMed ID: 16644338
[TBL] [Abstract][Full Text] [Related]
9. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Bakris GL; Cooper-Dehoff RM; Zhou Q; Kupfer S; Champion A; Pepine CJ;
Am J Cardiovasc Drugs; 2007; 7 Suppl 1():25-9. PubMed ID: 19845074
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
Pepine CJ; Handberg-Thurmond E; Marks RG; Conlon M; Cooper-DeHoff R; Volkers P; Zellig P
J Am Coll Cardiol; 1998 Nov; 32(5):1228-37. PubMed ID: 9809930
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
Niu Y; Gong Y; Langaee TY; Davis HM; Elewa H; Beitelshees AL; Moss JI; Cooper-Dehoff RM; Pepine CJ; Johnson JA
Circ Cardiovasc Genet; 2010 Dec; 3(6):548-55. PubMed ID: 21156931
[TBL] [Abstract][Full Text] [Related]
12. Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
Sava RI; Chen YE; Smith SM; Gong Y; Cooper-DeHoff RM; Keeley EC; Pepine CJ; Handberg EM
J Womens Health (Larchmt); 2020 Feb; 29(2):158-166. PubMed ID: 31403360
[No Abstract] [Full Text] [Related]
13. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Beitelshees AL; Navare H; Wang D; Gong Y; Wessel J; Moss JI; Langaee TY; Cooper-DeHoff RM; Sadee W; Pepine CJ; Schork NJ; Johnson JA
Circ Cardiovasc Genet; 2009 Aug; 2(4):362-70. PubMed ID: 20031608
[TBL] [Abstract][Full Text] [Related]
14. Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).
Zineh I; Cooper-Dehoff RM; Wessel TR; Arant CB; Sleight P; Geiser EA; Pepine CJ
Clin Cardiol; 2005 Jul; 28(7):321-8. PubMed ID: 16075824
[TBL] [Abstract][Full Text] [Related]
15. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
Elliott WJ; Hewkin AC; Kupfer S; Cooper-DeHoff R; Pepine CJ
J Clin Hypertens (Greenwich); 2005 Nov; 7(11):654-63. PubMed ID: 16278523
[TBL] [Abstract][Full Text] [Related]
16. Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Pepine CJ; Kowey PR; Kupfer S; Kolloch RE; Benetos A; Mancia G; Coca A; Cooper-DeHoff RM; Handberg E; Gaxiola E; Sleight P; Conti CR; Hewkin AC; Tavazzi L;
J Am Coll Cardiol; 2006 Feb; 47(3):547-51. PubMed ID: 16458134
[TBL] [Abstract][Full Text] [Related]
17. Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
Denardo SJ; Gong Y; Cooper-DeHoff RM; Farsang C; Keltai M; Szirmai L; Messerli FH; Bavry AA; Handberg EM; Mancia G; Pepine CJ
PLoS One; 2015; 10(4):e0122726. PubMed ID: 25835002
[TBL] [Abstract][Full Text] [Related]
18. ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients.
Grzegorzewska AE; Niepolski L; Świderska MK; Mostowska A; Stolarek I; Warchoł W; Figlerowicz M; Jagodziński PP
BMC Med Genet; 2018 Nov; 19(1):194. PubMed ID: 30413149
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
McDonough CW; Gong Y; Padmanabhan S; Burkley B; Langaee TY; Melander O; Pepine CJ; Dominiczak AF; Cooper-Dehoff RM; Johnson JA
Hypertension; 2013 Jul; 62(1):48-54. PubMed ID: 23690342
[TBL] [Abstract][Full Text] [Related]
20. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Cooper-Dehoff R; Cohen JD; Bakris GL; Messerli FH; Erdine S; Hewkin AC; Kupfer S; Pepine CJ;
Am J Cardiol; 2006 Oct; 98(7):890-4. PubMed ID: 16996868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
